Zepbound.®

Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for weight management and moderate-to-severe obstructive sleep apnea in adults¹,². The medication is indicated for adults with obesity (BMI ≥ 30) or those who are overweight (BMI 27–29.9) and have at least one weight-related health condition such as type 2 diabetes, hypertension, cardiovascular disease, or obstructive sleep apnea². Zepbound exerts its therapeutic effect by activating GIP and GLP-1 receptors, which regulate appetite, slow gastric emptying, and promote satiety—actions that collectively reduce caloric intake¹,³. In clinical trials, participants receiving Zepbound achieved average weight loss of 15–21% over 17 months depending on dose, significantly exceeding placebo outcomes, while also demonstrating improvements in blood glucose regulation, blood pressure, and lipid profiles⁴,⁵. The medication is administered as a once-weekly subcutaneous injection and is most effective when combined with reduced-calorie diet and regular physical activity¹,².

Common side effects of Zepbound include nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, fatigue, injection site reactions, heartburn, burping, and hair loss, which often occur during dose escalation and typically resolve within 1-2 weeks.³,⁶,⁷,⁸ Serious risks, though less common, encompass severe gastrointestinal issues such as pancreatitis or bowel obstruction, gallbladder problems like gallstones or cholecystitis, kidney damage from dehydration, severe allergic reactions, low blood sugar (especially in diabetics), thyroid tumors, and mental health changes including suicidal thoughts.³,⁶,⁷,⁹,¹⁰ Key safety considerations involve monitoring for symptoms like persistent abdominal pain radiating to the back, jaundice, swelling in the neck, or trouble breathing, and discontinuing use to seek immediate medical attention if they arise; it is contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.⁷,¹¹,¹² Patients should report bothersome effects to their healthcare provider, stay hydrated, and avoid rapid dose increases to minimize risks.³,⁸

Zepbound (tirzepatide) acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.¹³,¹⁴,¹⁵,¹⁶,¹⁷ It mimics endogenous incretin hormones, stimulating glucose-dependent insulin secretion from pancreatic beta cells while suppressing glucagon release from alpha cells, thereby improving glycemic control.¹⁴,¹⁶,¹⁸ Activation of these receptors in the brain and periphery reduces appetite, promotes satiety, and slows gastric emptying, leading to decreased food intake and caloric absorption.¹³,¹⁸,¹⁹,²⁰ Its structure includes a C20 fatty diacid moiety that enables albumin binding, prolonging its half-life for once-weekly dosing.¹⁴ These combined effects support fat mass reduction while preserving lean mass.¹⁹,²⁰